OP03.01: Tru‐cut biopsy in gynecological cancer: adequacy, accuracy, safety and clinical applicability

The aim of this study was to assess the adequacy, accuracy and safety of tru-cut biopsy. A retrospective population-based review of 328 biopsies was conducted. Indications for tru-cut biopsies were diagnosis of primary tumours, metastases and suspected recurrences. A tissue sample was considered adequate when the quality/quality was sufficient to identify the subtype/origin of the tumour. Accuracy was defined as agreement between the diagnosis of the tru-cut biopsy and the postoperative histology. Complications within 30 days after the biopsy procedure were registered. In total, 300 biopsies were identified as tru-cut biopsies. The overall adequacy was 86.3%, varying between 80.8% and 93.5%, respectively, when performed by a gynecological oncologist or a gynecologist with ultrasound diagnosis subspeciality. Sampling of a pelvic mass had a lower adequacy (81.6%) compared with sampling of the omentum (93.9%) or carcinomatosis (91.5%). The accuracy was 97.5%, and the complication rate was 1.3%. The tru-cut biopsy is a safe and reliable diagnostic method with a high accuracy and a good adequacy, depending on the site of the tissue sample, indications for the biopsy and the experience of the operator. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.